HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin
Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + paclitaxel showed no clear difference in clinical response ‐ stable disease compared with HAART + pegylated liposomal doxorubicin (moderate certainty).
1 finding from 1 review
- Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes onlyRR 0.63 [0.27, 1.45]1 study · 49 participantsModerate